Interaction of Dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system

Author： Striem S. Bar-Joseph A. Berkovitch Y. Biegon A.

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.338, Iss.3, 1997-11, pp. : 205-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist

By Eshhar N. Striem S. Kohen R. Tirosh O. Biegon A.

European Journal of Pharmacology, Vol. 283, Iss. 1, 1995-09 ,pp. : 19-29

Elsevier

Access to resources Recommend Favorite

Dexanabinol: Dexanabinone, HU 211, PA 50211, PRS 211007, Sinnabidol

Drugs in R&D, Vol. 4, Iss. 3, 2003-01 ,pp. : 185-187

Adis International

Access to resources Recommend Favorite

Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system

By Friese A. Seiller E. Quack G. Lorenz B. Kreuter J.

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 49, Iss. 2, 2000-03 ,pp. : 103-109

Elsevier

Access to resources Recommend Favorite

Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action

Current Drug Targets, Vol. 2, Iss. 3, 2001-09 ,pp. : 285-298

Bentham Science Publishers

Access to resources Recommend Favorite

Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801

By Olds M.E.

European Journal of Pharmacology, Vol. 306, Iss. 1, 1996-06 ,pp. : 23-32

Elsevier

Access to resources Recommend Favorite